ASCO GI 2023 | FIRE-4: evaluation of 1L efficacy of FOLFIRI/cetuximab in patients with RAS-WT mCRC

The FIRE-4 trial (NCT02934529) aims to evaluate the efficacy of early switch maintenance during first-line therapy and re-challenge with cetuximab in later-line treatment. In this video, Sebastian Stintzing, MD, Charite University Hospital, Berlin, Germany, discusses the results from an evaluation of first-line treatment efficacy of FOLFIRI/cetuximab in patients with RAS-wild type metastatic colorectal cancer (mCRC) receiving the first cycle of treatment with chemotherapy only. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ